KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) EBIT Margin: 2009-2025

Historic EBIT Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to 19.69%.

  • Teva Pharmaceutical Industries' EBIT Margin rose 2086.00% to 19.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.89%, marking a year-over-year increase of 802.00%. This contributed to the annual value of -1.83% for FY2024, which is 456.00% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported EBIT Margin of 19.69% as of Q3 2025, which was up 80.69% from 10.90% recorded in Q2 2025.
  • Teva Pharmaceutical Industries' EBIT Margin's 5-year high stood at 19.69% during Q3 2025, with a 5-year trough of -25.54% in Q2 2022.
  • For the 3-year period, Teva Pharmaceutical Industries' EBIT Margin averaged around 4.08%, with its median value being -0.12% (2024).
  • Per our database at Business Quant, Teva Pharmaceutical Industries' EBIT Margin surged by 12,518bps in 2021 and then plummeted by 4,043bps in 2022.
  • Over the past 5 years, Teva Pharmaceutical Industries' EBIT Margin (Quarterly) stood at 1.90% in 2021, then slumped by 2,610bps to -24.20% in 2022, then soared by 4,116bps to 16.96% in 2023, then tumbled by 1,765bps to -0.69% in 2024, then surged by 2,086bps to 19.69% in 2025.
  • Its EBIT Margin was 19.69% in Q3 2025, compared to 10.90% in Q2 2025 and 13.34% in Q1 2025.